Is the European Medical Products Authorisation Regulation Equipped to Cope with the Challenges of Nanomedicines?

Share/Save/Bookmark

Dorbeck-Jung, Bärbel and Chowdhury, Nupur (2011) Is the European Medical Products Authorisation Regulation Equipped to Cope with the Challenges of Nanomedicines? Law & Policy, 33 (2). pp. 276-303. ISSN 0265-8240

[img]PDF
Restricted to UT campus only
: Request a copy
216Kb
Abstract:This article analyses the emerging European regulatory activities in relation to nanopharmaceuticals. The central question is whether the regulatory responses are appropriate to cope with the regulatory problems nanomedicinal development is posing. The article explores whether the medical product regulations are robust enough, whether there are certain regulatory gaps, and whether the competent bodies have the expertise to evaluate nanomedicinal products when approval is applied for. Based on a social-constructive approach, the article identifies significant regulatory actors, their ideas on regulatory problems, and preliminary governance responses to them. It finds that the current dynamic regulatory structure appears robust enough to adapt to some of the technological challenges posed by
nanomedicines. It concludes that regulators have not yet responded adequately to
regulatory gaps related to definitions, classification and specific safety, quality, and efficacy standards that nanopharmaceutical development seems to require. As a consequence of these deficiencies legal certainty, a principle of high priority in European medical regulation policy, cannot be sufficiently provided.
Item Type:Article
Copyright:© 2011 The Author(s)
Faculty:
Management and Governance (SMG)
Research Group:
Link to this item:http://purl.utwente.nl/publications/78741
Official URL:http://dx.doi.org/10.1111/j.1467-9930.2011.00339.x
Export this item as:BibTeX
EndNote
HTML Citation
Reference Manager

 

Repository Staff Only: item control page

Metis ID: 271225